Free Trial
→ Trump's Law S.1582: $21T Dollar Revolution Coming (From Brownstone Research) (Ad)tc pixel Free KRYS Stock Alerts

Krystal Biotech (KRYS) Financials

Krystal Biotech logo
$186.13 -0.32 (-0.17%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$186.18 +0.05 (+0.02%)
As of 10/24/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Krystal Biotech

Annual Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89
Consolidated Net Income / (Loss)		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89
Net Income / (Loss) Continuing Operations		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89
Total Pre-Tax Income 		-1.15 -7.92 -11 -19 -32 -70 -140 13 95
Total Operating Income		 -1.14 -4.77 -12 -22 -33 -68 -145 -110 66
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48 270
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 51 291
Operating Revenue		 - - - - - 0.00 0.00 51 291
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.09 20
Operating Cost of Revenue		 - - - - - 0.00 - 3.09 20
Total Operating Expenses		 1.14 4.77 12 22 33 68 145 157 205
Selling, General & Admin Expense		 0.40 1.56 4.16 6.47 15 40 78 98 114
Research & Development Expense		 0.74 3.21 7.76 16 18 28 42 46 54
Other Special Charges / (Income)		 - - - - 0.00 0.00 25 13 38
Total Other Income / (Expense), net		 -0.01 -3.15 1.03 2.99 0.83 -1.30 5.22 123 30
Interest & Investment Income		 - - - - - 0.20 5.22 23 30
Other Income / (Expense), net		 -0.01 -3.15 1.03 - 0.83 0.00 0.00 100 0.00
Income Tax Expense		 - - - - - 0.00 0.00 1.97 6.20
Basic Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) ($3.13) ($5.49) $0.40 $3.12
Weighted Average Basic Shares Outstanding		 877.49K 10.31M 11.20M 15.90M 18.79M 22.20M 25.49M 27.15M 28.59M
Diluted Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) ($3.13) ($5.49) $0.39 $3.00
Weighted Average Diluted Shares Outstanding		 877.49K 10.31M 11.20M 15.90M 18.79M 22.20M 25.49M 27.75M 29.74M
Weighted Average Basic & Diluted Shares Outstanding		 877.49K 5.36M 11.20M 15.90M 18.79M 25.76M - 28.29M 28.81M

Quarterly Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -30 -32 -45 -33 81 8.69 0.93 16 27 45 36
Consolidated Net Income / (Loss)		 -30 -32 -45 -33 81 8.69 0.93 16 27 45 36
Net Income / (Loss) Continuing Operations		 -30 -32 -45 -33 81 8.69 0.93 16 27 45 36
Total Pre-Tax Income 		-30 -32 -45 -33 81 11 0.93 16 30 49 44
Total Operating Income		 -31 -35 -49 -38 -26 3.14 -6.68 8.57 22 41 36
Total Gross Profit		 0.00 - 0.00 0.00 8.56 39 43 64 77 86 83
Total Revenue		 0.00 - 0.00 0.00 8.56 42 45 70 84 91 88
Operating Revenue		 0.00 - 0.00 0.00 8.56 42 45 70 84 91 88
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 3.09 2.42 6.01 6.68 4.95 5.03
Operating Cost of Revenue		 0.00 - 0.00 0.00 - - 2.42 6.01 6.68 4.95 5.03
Total Operating Expenses		 31 35 49 38 34 36 50 56 55 45 47
Selling, General & Admin Expense		 20 24 24 26 24 25 26 28 29 31 33
Research & Development Expense		 12 11 12 12 11 11 11 16 14 14 14
Other Special Charges / (Income)		 0.00 - 13 0.00 0.00 - 13 13 13 - 0.00
Total Other Income / (Expense), net		 1.60 2.98 3.53 4.84 107 7.52 7.62 7.48 7.34 7.23 7.42
Interest & Investment Income		 1.60 - - 4.84 6.74 - - - 7.34 - 7.42
Income Tax Expense		 - - - 0.00 0.00 - - 0.48 2.59 - 7.86
Basic Earnings per Share		 ($1.17) ($1.23) ($1.76) ($1.25) $2.88 $0.53 $0.03 $0.54 $0.95 $1.60 $1.24
Weighted Average Basic Shares Outstanding		 25.62M 25.49M 25.71M 26.66M 28.04M 27.15M 28.30M 28.60M 28.72M 28.59M 28.82M
Diluted Earnings per Share		 ($1.17) ($1.23) ($1.76) ($1.25) $2.79 $0.61 $0.03 $0.53 $0.91 $1.53 $1.20
Weighted Average Diluted Shares Outstanding		 25.62M 25.49M 25.71M 26.66M 28.89M 27.75M 29.29M 29.64M 29.90M 29.74M 29.87M
Weighted Average Basic & Diluted Shares Outstanding		 25.75M 0.00 27.99M - 28.21M 28.29M 28.56M 28.73M 28.76M 28.81M 28.90M

Annual Cash Flow Statements for Krystal Biotech

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 1.92 48 54 84 81 73 -179 196 -13
Net Cash From Operating Activities		 -1.31 -3.89 -9.45 -19 -26 -48 -101 -89 123
Net Cash From Continuing Operating Activities		 -1.31 -3.89 -9.45 -19 -26 -48 -101 -89 123
Net Income / (Loss) Continuing Operations		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89
Consolidated Net Income / (Loss)		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89
Depreciation Expense		 0.00 0.02 0.14 1.09 1.85 1.85 2.64 5.01 5.97
Amortization Expense		 - - - - - 0.92 0.74 -1.28 0.75
Non-Cash Adjustments To Reconcile Net Income		 0.04 3.51 0.79 1.31 3.31 17 33 -65 73
Changes in Operating Assets and Liabilities, net		 -0.20 0.50 0.51 -2.00 0.93 2.05 2.66 -38 -45
Net Cash From Investing Activities		 -0.02 -0.21 -10 -4.99 -11 -227 -114 83 -163
Net Cash From Continuing Investing Activities		 -0.02 -0.21 -10 -4.99 -11 -227 -114 83 -163
Purchase of Property, Plant & Equipment		 -0.02 -0.21 -2.23 -6.40 -15 -68 -53 -12 -4.24
Purchase of Investments		 - - -8.09 -9.09 -3.21 -190 -319 -509 -458
Divestitures		 - - - - - 0.00 0.00 100 0.00
Sale and/or Maturity of Investments		 - - - 11 6.87 32 258 503 299
Net Cash From Financing Activities		 3.25 52 74 108 118 348 35 203 27
Net Cash From Continuing Financing Activities		 3.25 52 74 108 118 348 35 203 27
Issuance of Common Equity		 0.10 42 74 108 118 356 29 160 0.00
Other Financing Activities, net		 - - - - 0.00 -7.96 6.36 43 27
Effect of Exchange Rate Changes		 - - - - 0.00 0.00 -0.04 -0.16 -0.46
Cash Income Taxes Paid		 - - - - - - 0.00 0.00 5.67

Quarterly Cash Flow Statements for Krystal Biotech

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -32 -25 -21 135 97 -15 0.68 -13 28 -29 -36
Net Cash From Operating Activities		 -20 -22 -26 -34 -21 -7.23 16 -4.17 59 53 31
Net Cash From Continuing Operating Activities		 -20 -23 -26 -34 -21 -7.23 16 -4.17 59 53 31
Net Income / (Loss) Continuing Operations		 -30 -32 -45 -33 81 8.69 0.93 16 27 45 36
Consolidated Net Income / (Loss)		 -30 -32 -45 -33 81 8.69 0.93 16 27 45 36
Depreciation Expense		 0.98 -0.32 1.09 1.26 1.14 1.52 1.43 1.84 1.34 1.36 1.41
Amortization Expense		 - - 0.22 0.22 0.23 -1.95 0.18 0.19 0.19 0.19 0.22
Non-Cash Adjustments To Reconcile Net Income		 8.84 9.24 22 -3.19 -94 10 20 24 18 12 -20
Changes in Operating Assets and Liabilities, net		 0.33 -0.58 -3.69 0.73 -9.62 -26 -6.44 -45 13 -5.73 13
Net Cash From Investing Activities		 -15 -5.21 3.56 -16 105 -10 -26 -19 -34 -84 -55
Net Cash From Continuing Investing Activities		 -15 -5.21 3.56 -16 105 -10 -26 -19 -34 -84 -55
Purchase of Property, Plant & Equipment		 -14 -5.22 -5.38 -2.79 -1.78 -1.85 -1.26 -1.13 -1.05 -0.80 -6.20
Purchase of Investments		 -67 -104 -146 -174 -106 -83 -88 -113 -113 -143 -138
Sale of Property, Plant & Equipment		 - - - - - - - - - - 0.44
Sale and/or Maturity of Investments		 67 104 155 161 113 75 64 95 79 60 89
Net Cash From Financing Activities		 2.12 3.07 1.47 185 13 2.62 11 11 3.37 2.43 -12
Net Cash From Continuing Financing Activities		 2.12 3.07 1.47 185 13 2.62 11 11 3.37 2.43 -12
Other Financing Activities, net		 - 7.01 1.47 25 14 2.61 11 11 3.37 2.43 -12
Effect of Exchange Rate Changes		 - -0.04 - - 0.01 -0.14 0.19 -0.34 0.29 -0.59 0.17
Cash Income Taxes Paid		 - - - - - - - - 3.15 0.52 0.40

Annual Balance Sheets for Krystal Biotech

This table presents Krystal Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2022 12/31/2022 12/31/2023 12/31/2024
Total Assets		 2.18 50 116 209 311 558 558 818 1,056
Total Current Assets		 2.17 50 113 196 275 384 384 588 742
Cash & Equivalents		 1.92 50 104 188 268 162 162 358 345
Short-Term Investments		 - 0.00 8.09 6.17 2.99 217 217 174 253
Accounts Receivable		 - - - - - - 0.00 42 105
Inventories, net		 - - - - - - 0.00 6.99 27
Prepaid Expenses		 0.25 0.32 0.89 2.20 3.80 4.61 4.61 6.71 13
Plant, Property, & Equipment, net		 0.01 0.20 3.01 8.48 31 162 162 161 155
Total Noncurrent Assets		 0.00 0.00 0.45 4.67 4.91 13 13 69 159
Long-Term Investments		 - - - 0.50 0.00 4.62 4.62 62 152
Other Noncurrent Operating Assets		 - - 0.45 4.17 4.91 8.37 8.37 7.29 6.51
Total Liabilities & Shareholders' Equity		 2.18 50 116 209 311 558 558 818 1,056
Total Liabilities		 1.89 0.64 2.89 6.11 19 36 36 40 109
Total Current Liabilities		 0.04 0.64 2.60 3.33 15 29 29 33 102
Accounts Payable		 0.04 0.64 2.60 1.02 2.11 27 27 26 64
Accrued Expenses		 - - - 1.83 5.11 - - 5.98 37
Other Current Liabilities		 - - - 0.48 8.24 1.56 1.56 1.47 1.22
Total Noncurrent Liabilities		 1.85 0.00 0.29 2.78 3.31 7.37 7.37 6.62 7.46
Other Noncurrent Operating Liabilities		 - 0.00 0.29 2.78 3.31 7.37 7.37 6.62 7.46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.29 49 113 203 292 522 522 779 946
Total Preferred & Common Equity		 0.29 49 113 203 292 522 522 779 946
Total Common Equity		 -1.12 49 113 203 292 522 522 779 946
Common Stock		 0.03 59 133 242 363 804 804 1,048 1,127
Retained Earnings		 -1.15 -9.07 -20 -39 -71 -281 -281 -270 -181
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.00 0.01 0.01 -0.73 -0.73 0.64 -0.19

Quarterly Balance Sheets for Krystal Biotech

This table presents Krystal Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 12/31/2022 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 558 684 790 853 918 982 1,074
Total Current Assets		 384 484 582 602 683 713 767
Cash & Equivalents		 162 276 373 359 346 374 309
Short-Term Investments		 217 202 189 179 214 214 308
Accounts Receivable		 - - 9.32 46 103 97 103
Inventories, net		 - - 5.28 11 12 19 30
Prepaid Expenses		 4.61 6.49 5.47 6.49 7.75 8.96 17
Plant, Property, & Equipment, net		 162 164 164 160 159 157 151
Total Noncurrent Assets		 13 36 44 91 76 113 157
Long-Term Investments		 4.62 28 37 84 69 106 148
Other Noncurrent Operating Assets		 8.37 7.88 7.65 7.04 6.79 6.67 8.08
Total Liabilities & Shareholders' Equity		 558 684 790 853 918 982 1,074
Total Liabilities		 36 31 34 54 79 96 90
Total Current Liabilities		 29 24 28 48 72 90 79
Accounts Payable		 27 22 26 35 49 59 31
Accrued Expenses		 - - - 11 22 30 47
Other Current Liabilities		 1.56 1.53 1.50 1.43 1.36 1.29 1.36
Total Noncurrent Liabilities		 7.37 7.01 6.82 6.47 6.91 6.95 10
Other Noncurrent Operating Liabilities		 7.37 7.01 6.82 6.47 6.91 6.95 10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 522 653 756 799 839 886 985
Total Preferred & Common Equity		 522 653 756 799 839 886 985
Total Common Equity		 522 653 756 799 839 886 985
Common Stock		 804 1,013 1,035 1,068 1,093 1,110 1,129
Retained Earnings		 -281 -359 -279 -269 -253 -226 -145
Accumulated Other Comprehensive Income / (Loss)		 -0.73 -0.24 -0.38 -0.30 -0.63 1.51 0.39

Annual Metrics And Ratios for Krystal Biotech

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 473.02%
EBITDA Growth		 0.00% -587.89% -36.10% -95.30% -44.42% -116.08% -116.49% 95.77% 1,307.02%
EBIT Growth		 0.00% -588.70% -37.49% -102.78% -45.68% -112.25% -112.66% 93.30% 775.39%
NOPAT Growth		 0.00% -317.50% -149.71% -85.31% -49.45% -106.90% -112.66% 8.49% 166.04%
Net Income Growth		 0.00% -588.70% -37.49% -75.30% -68.52% -116.28% -101.20% 107.81% 715.58%
EPS Growth		 0.00% -12.98% 34.46% -23.71% -42.50% -83.04% -75.40% 107.10% 669.23%
Operating Cash Flow Growth		 0.00% -196.72% -142.80% -97.88% -39.56% -83.79% -109.79% 11.70% 238.98%
Free Cash Flow Firm Growth		 0.00% 0.00% -229.96% -129.00% -54.86% -370.06% 38.55% -36.84% 135.37%
Invested Capital Growth		 0.00% -154.17% 1,352.14% 496.04% 138.46% 564.87% 0.00% 33.28% 6.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 492.55% 20.29%
EBITDA Q/Q Growth		 0.00% 0.00% -26.73% -8.59% -12.13% -20.54% -9.53% 95.85% 124.97%
EBIT Q/Q Growth		 0.00% 0.00% -26.99% -9.62% -11.94% -20.17% -9.75% 93.41% 139.31%
NOPAT Q/Q Growth		 0.00% 0.00% -29.56% -9.62% -14.84% -20.17% -9.75% 10.00% 123.76%
Net Income Q/Q Growth		 0.00% 0.00% -26.99% -9.46% -18.52% -19.65% -7.90% 136.67% 70.24%
EPS Q/Q Growth		 0.00% 0.00% -76.36% -0.84% -17.12% -15.07% -5.37% 126.90% 44.23%
Operating Cash Flow Q/Q Growth		 0.00% -48.25% -17.27% -22.90% -4.09% -36.72% -1.44% 14.53% 94.84%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -22.56% -13.40% -135.21% 45.10% -13.78% 817.93%
Invested Capital Q/Q Growth		 0.00% 0.00% 73,350.00% 96.76% 35.60% 201.56% 0.00% 17.27% 2.67%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.90% 93.09%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.83% 24.92%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -216.43% 22.61%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19.19% 22.61%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.56% 30.69%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 84.76% 93.50%
Interest Burden Percent		 100.00% 100.00% 100.00% 86.45% 100.00% 101.90% 96.40% -132.59% 145.15%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.24% 6.50%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.60% 32.22%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -78.86% 28.09%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 59.28% -21.89%
Return on Equity (ROE)		 -397.92% -31.83% -13.39% -12.08% -13.00% -17.09% -26.80% 1.68% 10.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -677.35% -445.69% -238.14% -207.72% -73.42% -86.13% 25.80%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.41% 7.01%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.59% 9.51%
Return on Common Equity (ROCE)		 1,538.00% -30.93% -13.39% -12.08% -13.00% -17.09% -26.80% 1.68% 10.34%
Return on Equity Simple (ROE_SIMPLE)		 -397.92% -16.01% -9.62% -9.41% -11.01% -13.32% -26.80% 1.40% 9.42%
Net Operating Profit after Tax (NOPAT)		 -0.80 -3.34 -8.34 -15 -23 -48 -102 -93 61
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -183.45% 21.14%
Net Nonoperating Expense Percent (NNEP)		 -479.32% -18.44% -3.16% -2.37% -3.90% -6.65% -9.99% 21.26% 4.13%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -19.46% -11.95% 6.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.10% 6.91%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 194.09% 39.13%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.58% 18.44%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 310.33% 70.48%
Earnings before Interest and Taxes (EBIT)		 -1.15 -7.92 -11 -22 -32 -68 -145 -9.73 66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.15 -7.90 -11 -21 -30 -66 -142 -6.00 72
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.18 2.65 4.72 4.05 2.98 3.91 4.49 4.76
Price to Tangible Book Value (P/TBV)		 0.00 2.18 2.65 4.72 4.05 2.98 3.91 4.49 4.76
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 69.02 15.51
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 320.09 50.53
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.31% 1.98%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 128.38 87.54 43.76 8.46 11.96 15.75 19.09
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 57.30 12.93
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 51.87
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 57.17
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 61.15
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.43
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 76.36
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 6.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 6.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.25 -1.00 -0.99 -0.97 -0.94 -0.80 -0.73 -0.75 -0.78
Leverage Ratio		 7.55 1.05 1.02 1.03 1.05 1.07 1.07 1.06 1.09
Compound Leverage Factor		 7.55 1.05 1.02 0.89 1.05 1.09 1.03 -1.40 1.58
Debt to Total Capital		 86.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 86.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 65.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -52.39% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -2.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 101.37 62.84 94.64 38.16 25.42 32.99 53.24 25.67
Noncontrolling Interest Sharing Ratio		 486.51% 2.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 50.44 77.99 43.39 58.88 17.80 13.30 13.30 17.76 7.28
Quick Ratio		 44.72 77.49 43.05 58.22 17.56 13.14 13.14 17.35 6.89
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.01 -9.92 -23 -35 -165 -102 -139 49
Operating Cash Flow to CapEx		 -8,740.00% -1,852.38% -422.78% -292.08% -175.73% -70.15% -189.83% -752.64% 2,912.22%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -110.86 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -32.13 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -77.93 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.31
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.96
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.20
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.31 1.84
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.45
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 92.21
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 304.69
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,122.02 815.27
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3,122.02 -418.36
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.22 -0.12 1.47 8.73 21 138 138 185 197
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.31 1.52
Increase / (Decrease) in Invested Capital		 0.00 -0.33 1.58 7.27 12 118 0.00 46 12
Enterprise Value (EV)		 0.00 58 188 764 911 1,172 1,656 2,905 3,756
Market Capitalization		 0.00 108 300 959 1,182 1,556 2,040 3,499 4,506
Book Value per Share		 ($1.27) $4.83 $7.85 $11.72 $14.82 $23.48 $20.28 $27.61 $32.91
Tangible Book Value per Share		 ($1.27) $4.83 $7.85 $11.72 $14.82 $23.48 $20.28 $27.61 $32.91
Total Capital		 2.13 49 113 203 292 522 522 779 946
Total Debt		 1.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.08 -50 -112 -194 -271 -384 -384 -594 -750
Capital Expenditures (CapEx)		 0.02 0.21 2.23 6.40 15 68 53 12 4.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.20 -0.32 -1.71 -1.13 -12 -24 -24 23 43
Debt-free Net Working Capital (DFNWC)		 2.13 49 110 193 260 355 355 555 640
Net Working Capital (NWC)		 2.13 49 110 193 260 355 355 555 640
Net Nonoperating Expense (NNE)		 0.35 4.58 2.55 3.63 9.07 22 38 -104 -28
Net Nonoperating Obligations (NNO)		 -0.07 -50 -112 -194 -271 -384 -384 -594 -750
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.14 1.09 1.85 2.77 3.39 3.73 6.71
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 44.65% 14.64%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,094.33% 220.32%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,094.33% 220.32%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) $0.00 $0.00 $0.40 $3.12
Adjusted Weighted Average Basic Shares Outstanding		 877.49K 10.31M 11.20M 17.36M 22.19M 0.00 0.00 27.15M 28.59M
Adjusted Diluted Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) $0.00 $0.00 $0.39 $3.00
Adjusted Weighted Average Diluted Shares Outstanding		 877.49K 10.31M 11.20M 17.36M 22.19M 0.00 0.00 27.75M 29.74M
Adjusted Basic & Diluted Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 877.49K 5.36M 11.20M 15.90M 18.79M 0.00 0.00 28.29M 28.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.80 -3.34 -8.34 -15 -23 -48 -84 -82 96
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -162.55% 33.21%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.44% 32.82%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -45.76 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -32.03 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -91.56 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -77.83 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Krystal Biotech

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 879.91% 116.26% 94.88%
EBITDA Growth		 -104.96% -59.42% 3.44% -34.79% 347.32% 107.73% 105.35% 149.40% -68.21% 926.93% 845.04%
EBIT Growth		 -100.94% -58.93% 2.79% -35.36% 335.31% 109.02% 101.91% 142.17% -69.69% 737.90% 641.25%
NOPAT Growth		 -100.94% -58.93% 2.79% -32.33% -18.07% 112.89% 80.44% 131.21% 178.80% 1,219.09% 543.62%
Net Income Growth		 -91.48% -46.99% 9.34% -18.15% 370.51% 127.12% 102.06% 146.88% -66.34% 423.23% 3,734.01%
EPS Growth		 -67.14% -29.47% 11.56% -13.64% 338.46% 149.59% 101.70% 142.40% -67.38% 150.82% 3,900.00%
Operating Cash Flow Growth		 -171.37% -6.84% -68.82% 20.60% -7.81% 67.61% 160.74% 87.81% 377.29% 830.68% 94.92%
Free Cash Flow Firm Growth		 -175.96% 81.69% -13.87% 184.42% 60.82% -76.40% 63.80% -314.37% 69.21% 167.87% 65.14%
Invested Capital Growth		 201.56% 0.00% 82.65% 0.00% 13.65% 33.28% 20.25% 0.00% 21.80% 6.63% 23.94%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 392.55% 7.37% 55.32% 19.29% 8.71% -3.24%
EBITDA Q/Q Growth		 -12.32% -15.15% -35.39% 23.03% 306.10% -96.40% -54.42% 610.98% 32.64% 16.18% 35.82%
EBIT Q/Q Growth		 -11.89% -10.55% -40.42% 22.07% 294.51% -95.76% -70.29% 1,621.57% 39.81% 17.17% 37.63%
NOPAT Q/Q Growth		 -9.38% -10.55% -40.42% 22.07% 2.41% 112.07% -313.07% 224.35% 146.43% 102.03% -28.34%
Net Income Q/Q Growth		 -6.20% -7.38% -41.32% 26.68% 343.14% -89.24% -89.28% 1,570.39% 74.59% 67.33% -21.43%
EPS Q/Q Growth		 -6.36% -5.13% -43.09% 28.98% 323.20% -78.14% -95.08% 1,666.67% 71.70% 68.13% -21.57%
Operating Cash Flow Q/Q Growth		 54.28% -13.41% -17.14% -30.72% 37.92% 65.93% 319.69% -126.23% 1,512.12% -10.22% -41.39%
Free Cash Flow Firm Q/Q Growth		 -2.79% 78.75% -314.07% 193.35% -147.71% 4.35% 15.02% -452.78% 93.15% 310.84% -143.64%
Invested Capital Q/Q Growth		 14.68% 0.00% 6.32% -100.00% 0.00% 17.27% -4.08% 18.65% -8.74% 2.67% 11.49%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 92.66% 94.65% 91.45% 92.03% 94.57% 94.30%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 880.93% 6.43% 5.62% 25.70% 28.58% 30.55% 42.88%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -303.80% 7.44% -14.77% 12.19% 26.76% 45.40% 41.02%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 864.97% 7.44% 2.06% 22.83% 26.76% 28.84% 41.02%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 943.75% 20.63% 2.06% 22.15% 32.42% 49.90% 40.52%
Tax Burden Percent		 100.00% 100.81% 100.00% 100.00% 100.00% 81.56% 100.00% 97.03% 91.30% 93.56% 81.96%
Interest Burden Percent		 94.91% 91.44% 92.78% 87.28% 109.11% 339.72% 100.00% 100.00% 132.70% 184.93% 120.51%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.97% 8.70% 0.00% 18.04%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -17.58% 2.34% -8.74% 18.72% 33.82% 69.19% 56.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -39.31% 1.20% -10.09% 16.41% 32.78% 68.58% 55.70%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 30.21% -0.90% 7.84% -12.31% -25.81% -53.42% -43.33%
Return on Equity (ROE)		 -27.88% -26.80% -22.52% 0.00% 12.63% 1.43% -0.90% 6.42% 8.00% 15.77% 13.25%
Cash Return on Invested Capital (CROIC)		 -200.87% -73.42% -146.87% 0.00% -82.66% -86.13% -60.08% -219.98% -3.93% 25.80% 27.82%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 10.97% 0.55% 0.26% 4.14% 7.29% 8.94% 14.19%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 11.97% 1.52% 0.26% 4.01% 8.83% 15.47% 14.02%
Return on Common Equity (ROCE)		 -27.88% -26.80% -22.52% 0.00% 12.63% 1.43% -0.90% 6.42% 8.00% 15.77% 13.25%
Return on Equity Simple (ROE_SIMPLE)		 -24.84% 0.00% -20.72% 0.00% -3.94% 0.00% 7.15% 12.63% 5.91% 0.00% 12.59%
Net Operating Profit after Tax (NOPAT)		 -22 -24 -34 -27 -26 3.14 -6.68 8.31 20 41 30
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -303.80% 7.44% -14.77% 11.83% 24.43% 45.40% 33.62%
Net Nonoperating Expense Percent (NNEP)		 -2.10% -2.01% -2.28% 0.00% 21.73% 1.14% 1.35% 2.31% 1.04% 0.61% 0.88%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.66% - - - 0.40% - - - 4.37% 3.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 7.34% 5.35% 8.55% 7.97% 5.43% 5.70%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 276.96% 58.76% 57.59% 39.31% 34.25% 34.33% 37.11%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 124.23% 26.98% 24.21% 22.17% 16.12% 14.84% 16.17%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 401.19% 85.74% 109.43% 79.26% 65.27% 49.17% 53.27%
Earnings before Interest and Taxes (EBIT)		 -31 -35 -49 -38 74 3.14 0.93 16 22 26 36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -35 -48 -37 75 2.71 2.54 18 24 28 38
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.43 3.91 3.16 0.00 4.30 4.49 6.28 6.25 5.90 4.76 5.27
Price to Tangible Book Value (P/TBV)		 3.43 3.91 3.16 0.00 4.30 4.49 6.28 6.25 5.90 4.76 5.27
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 379.54 69.02 52.31 31.55 21.65 15.51 15.58
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 320.09 87.80 49.50 99.86 50.53 41.90
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.31% 1.14% 2.02% 1.00% 1.98% 2.39%
Enterprise Value to Invested Capital (EV/IC)		 10.15 11.96 10.58 0.00 16.84 15.75 24.84 21.98 23.67 19.09 20.19
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 309.57 57.30 45.82 27.77 18.78 12.93 13.28
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 140.92 51.87 38.41
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 165.22 57.17 40.79
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 165.22 61.15 45.42
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 71.60 30.43 31.97
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 76.36 80.33
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.80 -0.73 -0.81 0.00 -0.77 -0.75 -0.78 -0.75 -0.79 -0.78 -0.78
Leverage Ratio		 1.09 1.07 1.08 0.00 1.06 1.06 1.06 1.09 1.08 1.09 1.08
Compound Leverage Factor		 1.03 0.98 1.00 0.00 1.15 3.60 1.06 1.09 1.43 2.01 1.30
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 29.51 33.64 39.87 0.00 57.30 53.29 56.16 40.60 33.29 25.54 35.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.30 13.30 20.25 0.00 21.10 17.76 12.66 9.50 7.97 7.28 9.65
Quick Ratio		 13.14 13.14 19.98 0.00 20.72 17.35 12.29 9.23 7.66 6.89 9.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -115 -24 -101 94 -45 -43 -36 -202 -14 29 -13
Operating Cash Flow to CapEx		 -140.07% -428.00% -486.08% -1,225.45% -1,191.80% -391.55% 1,260.95% -368.52% 5,626.86% 6,597.13% 536.82%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.07 0.12 0.18 0.27 0.31 0.35
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.61 4.53 3.96 4.45
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.95 1.53 1.20 1.11
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.05 0.31 0.59 1.05 1.51 1.84 2.14
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.12 0.19 0.24 0.43 0.45 0.69
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 226.68 80.56 92.21 81.95
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 385.81 239.17 304.69 329.89
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 3,122.02 1,894.82 1,544.55 849.77 815.27 528.03
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -3,122.02 -1,894.82 -932.06 -530.04 -418.36 -116.19
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 138 138 147 0.00 157 185 177 210 192 197 219
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.06 0.31 0.59 1.58 1.38 1.52 1.68
Increase / (Decrease) in Invested Capital		 93 0.00 67 -121 19 46 30 210 34 12 42
Enterprise Value (EV)		 1,405 1,656 1,557 0.00 2,649 2,905 4,396 4,616 4,536 3,756 4,428
Market Capitalization		 1,789 2,040 2,063 3,029 3,247 3,499 5,019 5,244 5,230 4,506 5,194
Book Value per Share		 $20.35 $20.28 $25.35 $0.00 $27.00 $27.61 $28.25 $29.37 $30.83 $32.91 $34.18
Tangible Book Value per Share		 $20.35 $20.28 $25.35 $0.00 $27.00 $27.61 $28.25 $29.37 $30.83 $32.91 $34.18
Total Capital		 522 522 653 0.00 756 779 799 839 886 946 985
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -384 -384 -506 0.00 -599 -594 -622 -629 -694 -750 -765
Capital Expenditures (CapEx)		 14 5.22 5.38 2.79 1.78 1.85 1.26 1.13 1.05 0.80 5.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -24 -24 -17 0.00 -7.52 23 16 51 35 43 70
Debt-free Net Working Capital (DFNWC)		 355 355 460 0.00 555 555 555 611 624 640 687
Net Working Capital (NWC)		 355 355 460 0.00 555 555 555 611 624 640 687
Net Nonoperating Expense (NNE)		 7.83 7.71 11 6.58 -107 -5.56 -7.62 -7.26 -6.70 -4.10 -6.08
Net Nonoperating Obligations (NNO)		 -384 -384 -506 0.00 -599 -594 -622 -629 -694 -750 -765
Total Depreciation and Amortization (D&A)		 0.98 -0.32 1.31 1.48 1.37 -0.43 1.61 2.02 1.53 1.56 1.63
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -87.94% 44.65% 17.09% 30.87% 14.62% 14.64% 21.13%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 6,481.36% 1,094.33% 578.08% 367.51% 258.22% 220.32% 206.12%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 6,481.36% 1,094.33% 578.08% 367.51% 258.22% 220.32% 206.12%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.17) ($1.23) $0.00 $0.00 $2.88 $0.53 $0.03 $0.54 $0.95 $1.60 $1.24
Adjusted Weighted Average Basic Shares Outstanding		 25.62M 25.49M 0.00 0.00 28.04M 27.15M 28.30M 28.60M 28.72M 28.59M 28.82M
Adjusted Diluted Earnings per Share		 ($1.17) ($1.23) $0.00 $0.00 $2.79 $0.61 $0.03 $0.53 $0.91 $1.53 $1.20
Adjusted Weighted Average Diluted Shares Outstanding		 25.62M 25.49M 0.00 0.00 28.89M 27.75M 29.29M 29.64M 29.90M 29.74M 29.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.75M 0.00 0.00 0.00 28.21M 28.29M 28.56M 28.73M 28.76M 28.81M 28.90M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -24 -25 -27 -18 2.20 4.07 20 32 29 30
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -212.66% 5.21% 9.00% 29.08% 38.04% 31.78% 33.62%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 943.75% 25.29% 2.06% 22.83% 35.51% 53.34% 49.44%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Krystal Biotech (NASDAQ:KRYS) has shown solid financial progress over the past several quarters and years. Here is an analysis of the key financial trends based on income statements, cash flow, and balance sheets from Q3 2022 through Q1 2025.

  • Revenue Growth: Operating revenue steadily increased from $0 in early 2023 to $88.2 million in Q1 2025, indicating successful commercialization and market penetration.
  • Gross Profit Expansion: Gross profit rose significantly from $0 in early 2023 to $83.2 million by Q1 2025, aided by controlled costs of revenue.
  • Net Income Improvement: Net income turned positive from a loss of $45.3 million in Q1 2023 to a profit of $35.7 million in Q1 2025, reflecting improving profitability.
  • Earnings Per Share (EPS) Growth: Diluted EPS grew from a negative $1.76 in Q1 2023 to a positive $1.20 in Q1 2025, showing improved shareholder value.
  • Operating Income Turnaround: Operating income improved from a negative $48.8 million in Q1 2023 to a positive $36.2 million by Q1 2025, showing operational efficiencies.
  • Strong Cash Position: Cash and equivalents increased from $275.9 million in Q1 2023 to $308.8 million in Q1 2025, supporting liquidity and operational needs.
  • Increasing Investments: Short-term investments rose to $308.1 million in Q1 2025, reflecting a robust cash management strategy.
  • Fluctuating R&D Expenses: Research and development expenses were slightly variable but remain significant (~$10-15 million quarterly), which is typical for a biotech focused on innovation.
  • Consistent Selling, General & Admin Expenses: SG&A expenses ranged between $24 million and $33 million per quarter, reflecting stable operating costs aligned with growth phase.
  • Significant Investing Outflows: Consistent large purchases of investments and PP&E (property, plant, and equipment) resulted in negative net cash from investing activities, indicating ongoing capital expenditures and expansion investments.

Summary: Krystal Biotech demonstrates a clear upward trajectory in revenues and profitability in the last couple of years, alongside growing cash reserves and investments to support expanding operations. While operating and investing cash flows show significant cash use, this is typical for a high-growth biotech company investing in product development and infrastructure. EPS and net income improvement suggest strengthening financial health, making KRYS an interesting candidate for investors looking at emerging biotech firms with improving fundamentals.

10/25/25 12:58 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Krystal Biotech's Financials

When does Krystal Biotech's financial year end?

According to the most recent income statement we have on file, Krystal Biotech's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Krystal Biotech's net income changed over the last 8 years?

Krystal Biotech's net income appears to be on a downward trend, with a most recent value of $89.16 million in 2024, falling from -$1.15 million in 2016. The previous period was $10.93 million in 2023. Find out what analysts predict for Krystal Biotech in the coming months.

What is Krystal Biotech's operating income?
Krystal Biotech's total operating income in 2024 was $65.70 million, based on the following breakdown:
  • Total Gross Profit: $270.45 million
  • Total Operating Expenses: $204.76 million
How has Krystal Biotech's revenue changed over the last 8 years?

Over the last 8 years, Krystal Biotech's total revenue changed from $0.00 in 2016 to $290.52 million in 2024, a change of 29,051,500,000.0%.

How much debt does Krystal Biotech have?

Krystal Biotech's total liabilities were at $109.46 million at the end of 2024, a 175.6% increase from 2023, and a 5,682.3% increase since 2016.

How much cash does Krystal Biotech have?

In the past 8 years, Krystal Biotech's cash and equivalents has ranged from $1.92 million in 2016 to $358.33 million in 2023, and is currently $344.87 million as of their latest financial filing in 2024.

How has Krystal Biotech's book value per share changed over the last 8 years?

Over the last 8 years, Krystal Biotech's book value per share changed from -1.27 in 2016 to 32.91 in 2024, a change of -2,685.1%.


Related Companies

This page (NASDAQ:KRYS) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners
NEW LAW: Congress Approves Setup For Digital Dollar?
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...
Goldco Precious Metals | Sponsoredtc pixel
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...
Brownstone Research | Sponsoredtc pixel
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...
Angel Publishing | Sponsoredtc pixel
Move $1,000 into this stock before Nov 6
The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...
Altimetry | Sponsoredtc pixel
$4,200 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...
Weiss Ratings | Sponsoredtc pixel
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...
Chaikin Analytics | Sponsoredtc pixel